Tag Archives: biologic

Rare Diseases and Orphan Drugs Growth Favorable to Specialty Pharmacies

Biophama companies are increasingly interested in establishing relationships with  experienced specialty pharmacies to dispense rare disease drugs to patients

ACA Supreme Court Deliberations and Any Impact on Biosimilars?

If the court strikes down the ACA entirely, biosimilars on the U.S. market or in the FDA approval pipeline would have to either be grandfathered in or face a regulatory wind-down

Biologics by McKesson Expands Specialty Pharmacy Oncology Offerings

Biologics, as part of a recent reorganization, is now joining McKesson’s Provider Solutions business within the Pharmaceutical Solutions and Services (PSaS) business unit

AllianceRx Walgreens Prime Offers a Patented Cold-Chain Shipment Packaging Process

A new patented process for delivering specialty medicine will assure AllianceRx Walgreens Prime patients receive their medicine delivered at the correct temperature

Oncology Biosimilars: Opportunity or Not?

Oncology Biosimilars: Opportunity or Not? VBCC – April 2016, Vol 7, No 3 – Employers’ Perspective F. Randy Vogenberg, PhD, RPh, Partner Access Market Intelligence Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA The United States has the largest biologic drugs market and high prices for biologics, such as monoclonal antibodies, therapeutic proteins, immunomodulators, and […]

Impact of Commercial Insurance in 2017

Clinical trial collaborations – an idea whose time has come

Impact of Commercial Insurance in 2017 – Considerable attention and planning has been focused on the Medicare market, but as we see from the chart below, Medicare represents approximately 13% of the total population.   Employer 49% Medicaid 19% Medicare 13% Uninsured 10% Non-Group 6% Other Public 2% (Source: Kaiser Family Foundation) A recent Mercer […]

Specialty Drug Spend Under the Medical Benefit

Continuation in rising costs of specialty drugs and maybe accelerate in next 1-2 years: Randy Vogenberg

Specialty Drug Spend Under the Medical Benefit — Biologic, biotechnology based, rare disease or high cost pharmaceuticals—collectively known as specialty drugs—can be covered under the pharmacy benefit, the medical benefit, or both depending on the plan sponsors’ benefit design required of the payor. On average, up to 50% of specialty drugs are covered under the […]